Values of high sensitive troponin T in long-term survivors of childhood cancer treated with anthracyclines

Pourier, Milanthy S.; Kapusta, Livia; Gennip, Aniek van; Bökkerink, J.P.M.; Loonen, Jacqueline J.; Bellersen, Louise; Mavinkurve‐Groothuis, Annelies M. C.

doi:10.1016/j.cca.2014.12.011

Cited by 18 publications

(42 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cut-off values for children were defined in the studies as age-specific and sex-specific values previously reported by Nir et al 29 31 32 and Albers et al 13 33. Also, sex-specific and age-specific cut-off values defined by Fradley et al 34 (ranging from 42.5 to 106.4 ng/L in males and 111.0–215.9 ng/mL in females depending on age) were used 32. Abnormal NT-proBNP values were seen in 5.3% up to 13% of the patients; we did not observe a relation with NT-proBNP cut-off values (table 2).…”

Section: Resultsmentioning

confidence: 99%

Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review

Leerink

Verkleij

Feijen

et al. 2018

Heart

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review

Leerink

Verkleij

Feijen

et al. 2018

Heart

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both studies, hence, validate the importance of using conventional troponin for surveillance post-chemotherapy as both a sensitive and reproducible marker of myocardial dysfunction, prior to development of HF. There is also increasing data emerging from survivors of childhood cancers which shows that cTnI and hs-TnI were not consistently elevated in patients who developed LV dysfunction on imaging [ 68 – 70 ]. Hence, these studies demonstrate that although troponin is a sensitive marker during and early after chemotherapy, it is not a sensitive marker for ongoing surveillance of subclinical cardiotoxicity post-chemotherapy, when compared to other biomarkers such as NPs.…”

Section: Cardiac Troponinmentioning

confidence: 99%

The Role of Biomarkers in Cardio-Oncology

Ananthan

Lyon

2020

J. of Cardiovasc. Trans. Res.

119

View full text Add to dashboard Cite

In the field of cardio-oncology, it is well recognised that despite the benefits of chemotherapy in treating and possibly curing cancer, it can cause catastrophic damage to bystander tissues resulting in a range of potentially of life-threatening cardiovascular toxicities, and leading to a number of damaging side effects including heart failure and myocardial infarction. Cardiotoxicity is responsible for significant morbidity and mortality in the long-term in oncology patients, specifically due to left ventricular dysfunction. There is increasing emphasis on the early use of biomarkers in order to detect the cardiotoxicity at a stage before it becomes irreversible. The most important markers of cardiac injury are cardiac troponin and natriuretic peptides, whilst markers of inflammation such as interleukin-6, C-reactive protein, myeloperoxidase, Galectin-3, growth differentiation factor-15 are under investigation for their use in detecting cardiotoxicity early. In addition, microRNAs, genome-wide association studies and proteomics are being studied as novel markers of cardiovascular injury or inflammation. The aim of this literature review is to discuss the evidence base behind the use of these biomarkers for the detection of cardiotoxicity.

show abstract

“…Survivors of childhood cancers represent a growing group of patients studied to screen for late adverse cardiac effects from chemotherapy agents. Multiple studies have shown that in childhood cancer survivors who were treated with anthracycline therapy, cTn and hs-cTn were not elevated in patients who developed cardiac dysfunction on imaging [18][19][20]. These studies demonstrate that troponin may not be a sensitive marker for late onset sub-clinical cardio-toxicity.…”

Section: Troponinmentioning

confidence: 86%

The Role of Biomarkers in Detection of Cardio-toxicity

et al. 2017

View full text Add to dashboard Cite

The goal of this paper is to review the current literature on the role of biomarkers in the detection and management of patients with cardio-oncologic disease. The role of biomarker surveillance in patients with known cardiac disease, as a result of chemotherapy or with the potential to develop cardio-toxicity, will be discussed. In addition, the studies surrounding sub-clinical cardiac toxicity monitoring during therapy, identification of high-risk patients prior to therapy, and tailoring oncologic therapies to potential biomarker risk profiles are reviewed. Based on evidence, to date, troponin and natriuretic peptides have the greatest potential to detect sub-clinical cardiac dysfunction and even tailor therapy to prevent progression based on biomarker profiles. Finally, future directions for potential utilization of novel biomarkers for the improvement of care of patients in the field of cardio-oncology are discussed.

show abstract

Values of high sensitive troponin T in long-term survivors of childhood cancer treated with anthracyclines

Cited by 18 publications

References 35 publications

Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review

Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review

The Role of Biomarkers in Cardio-Oncology

The Role of Biomarkers in Detection of Cardio-toxicity

Contact Info

Product

Resources

About